Asceneuron scoops One Nucleus BioNewsRound Award

30.12.2015 11:24

Asceneuron is this year’s winner of the coveted One Nucleus BioNewsRound Award. The Swiss start-up has prevailed over five nominees including Astra Zeneca and Immunocore.

Harriet Fear, CEO of One Nucleus, described competition as fierce, with the votes having been cast by the sector in an on-line, and therefore peer reviewed, open voting process.

“The winner is a fantastic example of what can be achieved when brilliant science, a collaborative spirit and a fantastic team come together,” said Harriet Fear. “The criteria for the Award are about great impact on and for the company, the sector and most importantly of all - the patient. We were overwhelmed by the response to the Award, which recognises not only the impact of the project, but also how well it was communicated to the sector at large.”

”Asceneuron’s ASN-561 inhibitor of the O-GlcNAcase enzyme has been shown in preclinical models to reduce the build-up of toxic neurofibrillary tangles consisting of tau protein in the brain” explains Dr. Dirk Beher, Chief Executive Officer and a co-founder of Asceneuron. “If shown to be safe and tolerated this molecule will enable us to explore ASN-561 as a potential drug for a variety of diseases caused by these neurofibrillary tangles. We are thrilled by the Award in recognition of the hard work the team has put into ultimately bringing innovation to patients in an area of high unmet medical need” he added.

“We are delighted to see that the achievements of Asceneuron, through its ground breaking work on tau-related diseases, along with the recent sizeable financing, with Sofinnova Partners, SR One, Johnson & Johnson Innovation - JJDC and Kurma Partners joining us, have helped earn this prestigious award.” said Dr. Hakan Goker, Senior Investment Director at MS Ventures, the strategic corporate venture capital fund of the healthcare business of Merck.


Please login or
register to comment

Please login or sign up to comment. Commenting guidelines




By continuing to use this website you agree with our TERMS AND CONDITIONS